Clonal evolution of glioblastoma under therapy

Jiguang Wang, Emanuela Cazzato, Erik Ladewig, Veronique Frattini, Daniel I S Rosenbloom, Sakellarios Zairis, Francesco Abate, Zhaoqi Liu, Oliver Elliott, Yong Jae Shin, Jin Ku Lee, In Hee Lee, Woong Yang Park, Marica Eoli, Andrew J. Blumberg, Anna Lasorella, Do Hyun Nam, Gaetano Finocchiaro, Antonio Iavarone, Raul Rabadan

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. To better understand how GBM evolves, we analyzed longitudinal genomic and transcriptomic data from 114 patients. The analysis shows a highly branched evolutionary pattern in which 63% of patients experience expression-based subtype changes. The branching pattern, together with estimates of evolutionary rate, suggests that relapse-associated clones typically existed years before diagnosis. Fifteen percent of tumors present hypermutation at relapse in highly expressed genes, with a clear mutational signature. We find that 11% of recurrence tumors harbor mutations in LTBP4, which encodes a protein binding to TGF-β. Silencing LTBP4 in GBM cells leads to suppression of TGF-β activity and decreased cell proliferation. In recurrent GBM with wild-type IDH1, high LTBP4 expression is associated with worse prognosis, highlighting the TGF-β pathway as a potential therapeutic target in GBM.

Original languageEnglish
Pages (from-to)768-776
Number of pages9
JournalNature Genetics
Volume48
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

Clonal Evolution
Glioblastoma
Recurrence
Therapeutics
Protein Binding
Brain Neoplasms
Neoplasms
Clone Cells
Cell Proliferation
Mutation
Genes

ASJC Scopus subject areas

  • Genetics

Cite this

Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D. I. S., Zairis, S., ... Rabadan, R. (2016). Clonal evolution of glioblastoma under therapy. Nature Genetics, 48(7), 768-776. https://doi.org/10.1038/ng.3590

Clonal evolution of glioblastoma under therapy. / Wang, Jiguang; Cazzato, Emanuela; Ladewig, Erik; Frattini, Veronique; Rosenbloom, Daniel I S; Zairis, Sakellarios; Abate, Francesco; Liu, Zhaoqi; Elliott, Oliver; Shin, Yong Jae; Lee, Jin Ku; Lee, In Hee; Park, Woong Yang; Eoli, Marica; Blumberg, Andrew J.; Lasorella, Anna; Nam, Do Hyun; Finocchiaro, Gaetano; Iavarone, Antonio; Rabadan, Raul.

In: Nature Genetics, Vol. 48, No. 7, 01.07.2016, p. 768-776.

Research output: Contribution to journalArticle

Wang, J, Cazzato, E, Ladewig, E, Frattini, V, Rosenbloom, DIS, Zairis, S, Abate, F, Liu, Z, Elliott, O, Shin, YJ, Lee, JK, Lee, IH, Park, WY, Eoli, M, Blumberg, AJ, Lasorella, A, Nam, DH, Finocchiaro, G, Iavarone, A & Rabadan, R 2016, 'Clonal evolution of glioblastoma under therapy', Nature Genetics, vol. 48, no. 7, pp. 768-776. https://doi.org/10.1038/ng.3590
Wang J, Cazzato E, Ladewig E, Frattini V, Rosenbloom DIS, Zairis S et al. Clonal evolution of glioblastoma under therapy. Nature Genetics. 2016 Jul 1;48(7):768-776. https://doi.org/10.1038/ng.3590
Wang, Jiguang ; Cazzato, Emanuela ; Ladewig, Erik ; Frattini, Veronique ; Rosenbloom, Daniel I S ; Zairis, Sakellarios ; Abate, Francesco ; Liu, Zhaoqi ; Elliott, Oliver ; Shin, Yong Jae ; Lee, Jin Ku ; Lee, In Hee ; Park, Woong Yang ; Eoli, Marica ; Blumberg, Andrew J. ; Lasorella, Anna ; Nam, Do Hyun ; Finocchiaro, Gaetano ; Iavarone, Antonio ; Rabadan, Raul. / Clonal evolution of glioblastoma under therapy. In: Nature Genetics. 2016 ; Vol. 48, No. 7. pp. 768-776.
@article{76f9ee32b06648309b419358eb495893,
title = "Clonal evolution of glioblastoma under therapy",
abstract = "Glioblastoma (GBM) is the most common and aggressive primary brain tumor. To better understand how GBM evolves, we analyzed longitudinal genomic and transcriptomic data from 114 patients. The analysis shows a highly branched evolutionary pattern in which 63{\%} of patients experience expression-based subtype changes. The branching pattern, together with estimates of evolutionary rate, suggests that relapse-associated clones typically existed years before diagnosis. Fifteen percent of tumors present hypermutation at relapse in highly expressed genes, with a clear mutational signature. We find that 11{\%} of recurrence tumors harbor mutations in LTBP4, which encodes a protein binding to TGF-β. Silencing LTBP4 in GBM cells leads to suppression of TGF-β activity and decreased cell proliferation. In recurrent GBM with wild-type IDH1, high LTBP4 expression is associated with worse prognosis, highlighting the TGF-β pathway as a potential therapeutic target in GBM.",
author = "Jiguang Wang and Emanuela Cazzato and Erik Ladewig and Veronique Frattini and Rosenbloom, {Daniel I S} and Sakellarios Zairis and Francesco Abate and Zhaoqi Liu and Oliver Elliott and Shin, {Yong Jae} and Lee, {Jin Ku} and Lee, {In Hee} and Park, {Woong Yang} and Marica Eoli and Blumberg, {Andrew J.} and Anna Lasorella and Nam, {Do Hyun} and Gaetano Finocchiaro and Antonio Iavarone and Raul Rabadan",
year = "2016",
month = "7",
day = "1",
doi = "10.1038/ng.3590",
language = "English",
volume = "48",
pages = "768--776",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Clonal evolution of glioblastoma under therapy

AU - Wang, Jiguang

AU - Cazzato, Emanuela

AU - Ladewig, Erik

AU - Frattini, Veronique

AU - Rosenbloom, Daniel I S

AU - Zairis, Sakellarios

AU - Abate, Francesco

AU - Liu, Zhaoqi

AU - Elliott, Oliver

AU - Shin, Yong Jae

AU - Lee, Jin Ku

AU - Lee, In Hee

AU - Park, Woong Yang

AU - Eoli, Marica

AU - Blumberg, Andrew J.

AU - Lasorella, Anna

AU - Nam, Do Hyun

AU - Finocchiaro, Gaetano

AU - Iavarone, Antonio

AU - Rabadan, Raul

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Glioblastoma (GBM) is the most common and aggressive primary brain tumor. To better understand how GBM evolves, we analyzed longitudinal genomic and transcriptomic data from 114 patients. The analysis shows a highly branched evolutionary pattern in which 63% of patients experience expression-based subtype changes. The branching pattern, together with estimates of evolutionary rate, suggests that relapse-associated clones typically existed years before diagnosis. Fifteen percent of tumors present hypermutation at relapse in highly expressed genes, with a clear mutational signature. We find that 11% of recurrence tumors harbor mutations in LTBP4, which encodes a protein binding to TGF-β. Silencing LTBP4 in GBM cells leads to suppression of TGF-β activity and decreased cell proliferation. In recurrent GBM with wild-type IDH1, high LTBP4 expression is associated with worse prognosis, highlighting the TGF-β pathway as a potential therapeutic target in GBM.

AB - Glioblastoma (GBM) is the most common and aggressive primary brain tumor. To better understand how GBM evolves, we analyzed longitudinal genomic and transcriptomic data from 114 patients. The analysis shows a highly branched evolutionary pattern in which 63% of patients experience expression-based subtype changes. The branching pattern, together with estimates of evolutionary rate, suggests that relapse-associated clones typically existed years before diagnosis. Fifteen percent of tumors present hypermutation at relapse in highly expressed genes, with a clear mutational signature. We find that 11% of recurrence tumors harbor mutations in LTBP4, which encodes a protein binding to TGF-β. Silencing LTBP4 in GBM cells leads to suppression of TGF-β activity and decreased cell proliferation. In recurrent GBM with wild-type IDH1, high LTBP4 expression is associated with worse prognosis, highlighting the TGF-β pathway as a potential therapeutic target in GBM.

UR - http://www.scopus.com/inward/record.url?scp=84976318961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976318961&partnerID=8YFLogxK

U2 - 10.1038/ng.3590

DO - 10.1038/ng.3590

M3 - Article

VL - 48

SP - 768

EP - 776

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 7

ER -